Pathophysiological explanation of cardiovascular benefits of sodium-glucose cotransporter-2 inhibitors by neurotrophic theory

被引：0
作者：
Hristova, Mariyana [1 ]
机构：
[1] Med Ctr Varna, Div Endocrinol, Varna, Bulgaria
来源：
MEDICAL HYPOTHESES | 2017年 / 102卷
关键词：
TYPE-2; DIABETES-MELLITUS; METABOLIC SYNDROME; SGLT2; INHIBITORS; BLOOD-PRESSURE; KIDNEY-DISEASE; HYPOTHESIS; OUTCOMES; DAPAGLIFLOZIN; REABSORPTION; METAANALYSIS;
D O I：
10.1016/j.mehy.2017.02.021
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
[No abstract available]
引用
收藏
页码：61 / 64
页数：4
相关论文
共 50 条
  • [1] The pleiotropic cardiovascular effects of sodium-glucose cotransporter-2 inhibitors
    Tanna, Monique S.
    Goldberg, Lee R.
    CURRENT OPINION IN CARDIOLOGY, 2021, 36 (06) : 764 - 768
  • [2] Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease
    Aftab, Saba
    Suresh, Rishwanth Vetrivel
    Sherali, Nazleen
    Daniyal, Muhammad
    Tsouklidis, Nicholas
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (10)
  • [3] Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
    Heerspink, Hiddo J. L.
    Kosiborod, Mikhail
    Inzucchi, Silvio E.
    Cherney, David Z. I.
    KIDNEY INTERNATIONAL, 2018, 94 (01) : 26 - 39
  • [4] Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors as a Dual Therapeutic Target for Cardiovascular and Renal Health: A Narrative Review
    Al Rashid, Sulthan
    Madar, Inamul Hasan
    Misbah, Iffath
    Dhanabalan, Kamalakannan
    Balasubramanian, Rajkapoor
    Maideen, Naina Mohamed Pakkir
    IBNOSINA JOURNAL OF MEDICINE AND BIOMEDICAL SCIENCES, 2025,
  • [5] Cardiovascular and renal benefits of sodium-glucose cotransporter-2 inhibitors: pathophysiologic mechanisms and clinical evidence
    Small, Andre M.
    Wiviott, Stephen D.
    MINERVA CARDIOLOGY AND ANGIOLOGY, 2024,
  • [6] Sodium-glucose cotransporter-2 inhibitors: where and when?
    Cowie, Martin R.
    FUTURE CARDIOLOGY, 2020, 17 (03) : 403 - 406
  • [7] Effects of sodium-glucose cotransporter-2 inhibitors on the cardiovascular and renal complications of type 2 diabetes
    Chilton, Robert J.
    DIABETES OBESITY & METABOLISM, 2020, 22 (01) : 16 - 29
  • [8] The Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
    Patel, Dhiren K.
    Strong, Jodi
    DIABETES THERAPY, 2019, 10 (05) : 1771 - 1792
  • [9] Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease
    Rastogi, Anjay
    Januzzi, James L., Jr.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (08)
  • [10] Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide
    Simes, Bryce C.
    MacGregor, Gordon G.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 2125 - 2136
12345